Table 1 Summary of therapeutic outcomes for Cu^II(atsm) across multiple mutant SOD1 mouse models of ALS.

Study	Mouse model	Genetic background	Age when treatment commenced	Daily dose (mg kg⁻¹ body weight)	Administration route	Increase in survival ^#
Soon et al.⁹	Low copy SOD1^G93A	Congenic; C57BL6	140 days	30 (5 days week⁻¹)	Oral	14%
Soon et al.⁹	Low copy SOD1^G93A	Congenic; C57BL6	200 days	30 (5 days week⁻¹)	Oral	10%
McAllum et al.⁷	High copy SOD1^G37R	Congenic; C57BL6	40 days	10 (7 days week⁻¹)	Oral	8%
McAllum et al.⁷	High copy SOD1^G37R	Congenic; C57BL6	40 days	30 (7 days week⁻¹)	Oral	18%
McAllum et al.⁷	High copy SOD1^G37R	Congenic; C57BL6	40 days	60 (7 days week⁻¹)	Oral	26%
McAllum et al.⁷	High copy SOD1^G37R	Congenic; C57BL6	149 days ^*	60 (7 days week⁻¹)	Oral	12%
Roberts et al.⁸	High copy SOD1^G37R	Congenic; C57BL6	40 days	30 (7 days week⁻¹)	Oral	18% ^§
Williams et al.¹⁰	High copy SOD1^G93A	Mixed; B6SJL	5 days	200 (7 days week⁻¹)	Transdermal	25%
Williams et al.¹⁰	High copy SOD1^G93A	Mixed; B6SJL	50 days	200 (7 days week⁻¹)	Transdermal	19%
Williams et al.¹⁰	High copy SOD1^G93A x CCS	Mixed; B6SJL	Prenatal	60 (7 days week⁻¹)	Transdermal	2,800%
Present study	High copy SOD1^G93A	Mixed; B6SJL	50 days	100 (7 days week⁻¹)	Oral	9%

^#Increase in mean survival relative to sham treated mice.
^*Treatment commenced after individual mice lost 20% of their basal pre-symptom functionality on the rotarod test for locomotive function and 149 days is the mean age at which all mice included in the study reached this phenotypic criterion.
^§Performed concurrently with the McAllum et al. study. These survival data were presented in the McAllum et al. paper and therefore not re-published in the Roberts et al. paper which instead reported other therapeutic outcomes and mechanism of action data.

Quick links

Search